Cosău Diana Elena, Costache Enache Irina Iuliana, Costache Alexandru Dan, Tudorancea Ionuț, Ancuța Codrina, Șerban Dragomir Nicolae, Bădescu Codruța Minerva, Loghin Cătălin, Șerban Ionela Lăcrămioara
Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Clinical Rehabilitation Hospital, 700661 Iasi, Romania.
Life (Basel). 2025 Apr 9;15(4):629. doi: 10.3390/life15040629.
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which predominantly affects joints, but it can also lead to significant extra-articular complications, particularly cardiovascular disease (CVD). Chronic systemic inflammation promotes endothelial dysfunction and accelerates atherosclerosis, increasing cardiovascular risk.
Current data were analyzed to explore the mechanisms between RA and CVD, focusing on systemic inflammation, pro-inflammatory cytokine patways (IL-1, IL-6, TNF, and JAK-STAT), and their interactions with traditional cardiovascular risk factors. Recent studies and clinical guidelines were reviewed to highlight gaps and advances in risk assessment and management.
Persistent disease activity and the presence of autoantibodies significantly increase cardiovascular risk in RA contributing to atherosclerosis and major cardiovascular events. Data also suggest that anti-inflammatory treatments, including methotrexate and biologic agents, may lower this risk.
This review highlights the pathophysiological mechanisms between RA and CVD, and the need for early diagnosis and active monitoring to identify and assess cardiovascular risk. A multidisciplinary approach, involving rheumatologists and cardiologists is essential for optimizing cardiovascular risk management and improving patient outcomes. Optimization of cardiovascular risk management strategies in patients with RA should be an essential component of current medical practice, with the main goal of reducing morbidity and mortality from cardiovascular complications.
类风湿关节炎(RA)是一种自身免疫性炎症性疾病,主要影响关节,但也可导致严重的关节外并发症,尤其是心血管疾病(CVD)。慢性全身性炎症会促进内皮功能障碍并加速动脉粥样硬化,增加心血管风险。
分析当前数据以探索RA与CVD之间的机制,重点关注全身性炎症、促炎细胞因子途径(IL-1、IL-6、TNF和JAK-STAT)及其与传统心血管危险因素的相互作用。回顾近期研究和临床指南以突出风险评估和管理方面的差距与进展。
持续的疾病活动和自身抗体的存在会显著增加RA患者的心血管风险,导致动脉粥样硬化和重大心血管事件。数据还表明,包括甲氨蝶呤和生物制剂在内的抗炎治疗可能会降低这种风险。
本综述强调了RA与CVD之间的病理生理机制,以及早期诊断和积极监测以识别和评估心血管风险的必要性。风湿科医生和心脏病专家参与的多学科方法对于优化心血管风险管理和改善患者预后至关重要。优化RA患者的心血管风险管理策略应是当前医疗实践的重要组成部分,主要目标是降低心血管并发症的发病率和死亡率。